ReviewBlood advances2020
Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?
Review in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Development and validation of a deep learning model to predict heparin response in critically ill patients with deep vein thrombosis receiving continuous intravenous heparin infusion.Blood science (Baltimore, Md.) · 2026Article
- Venous Thromboembolism in Inherited Platelet Disorders: A Clinical Challenge.Diagnostics (Basel, Switzerland) · 2025Review
- Three Year Follow-Up of Reduced Dose of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: An Ambispective Cohort Study.Diagnostics (Basel, Switzerland) · 2025Article
- Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients.Cancer medicine · 2025Article
- Is pulmonary embolism a chronic disease?Clinical medicine (London, England) · 2025Review
- Association of clonal haematopoiesis with recurrent venous thromboembolism: A case-control study.British journal of haematology · 2025Article
- Is interrupting anticoagulation for thrombosis risk stratification safe?Blood vessels, thrombosis & hemostasis · 2024Article
- Incidence and Risk Factors of Deep Vein Thrombosis after Foot and Ankle Surgery.Clinics in orthopedic surgery · 2024Article
- Retrospective cross-sectional analysis of concurrent VTE diagnosis in hospitalised socially excluded individuals in Ireland.BMJ open · 2024Article
- Thrombin Generation Is Associated with Venous Thromboembolism Recurrence, but Not with Major Bleeding and Death in the Elderly: A Prospective Multicenter Cohort Study.Journal of clinical medicine · 2023Article
- Venous thromboembolism recurrence among one-and-done direct oral anticoagulant users: a retrospective longitudinal study.International journal of clinical pharmacy · 2023Article
- Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review.Research and practice in thrombosis and haemostasis · 2023Article
- Risk factors, diagnosis and management of venous thromboembolic disease in pregnancy.Breathe (Sheffield, England) · 2022Review
- Utility of a recurrence prediction tool (DASH score) at a single centre after unprovoked venous thromboembolism: patient uptake of the tool and short term risks of stopping anticoagulation.Journal of thrombosis and thrombolysis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent venous thromboembolism (VTE, or deep vein thrombosis and pulmonary embolism) is associated with mortality and long-term morbidity. The circumstances in which an index VTE event occurred are crucial when personalized VTE recurrence risk is assessed. Patients who experience a VTE event in the setting of a transient major risk factor (such as surgery associated with general anesthesia for >30 minutes) are predicted to have a low VTE recurrence risk following discontinuation of anticoagulation, and limited-duration anticoagulation is generally recommended. In contrast, those patients whose VTE event occurred in the absence of risk factors or who have persistent risk factors have a higher VTE recurrence risk. Here, we review the literature surrounding VTE recurrence risk in a range of clinical conditions. We describe gender-specific risks, including VTE recurrence risk following hormone- and pregnancy-associated VTE events. Finally, we discuss how the competing impacts of VTE recurrence and bleeding have shaped international guideline recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.